Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.
Copyright West LLC. Minimum 15 minutes delayed.
Nov 9, 2018 at 6:00 PM EST
Oct 22, 2018 at 8:00 AM EDT
Oct 19 - Oct 23, 2018
November 12, 2018Neon Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
November 9, 2018Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
November 7, 2018Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors